Patent ID: 8026217

Claim:
A method comprising administering a PKG pathway pharmacological inhibitor selected from the group consisting of: KT5823; (Rp)-8-bromo-PET-cyclic GMPS; (Rp)-8-pCPT-cyclic GMPS, TEA; Rp-8-Br-cGMPS, Na; DT-3; DT-2; amino acid sequence RKRARKE (SEQ ID NO: 5); Okadaic acid; Microcystin; Calyculin; Cantharidin; 4H-8-Bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one; 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ); and 6-Anilino-5,8-quinolinequinone to a patient having a medical condition selected from the group consisting of: neuronal damage from spinal cord injury, neuronal damage from stroke, neural anoxia, spreading depression, and migraine, in an amount effective for preventing failure of neural function associated with one or both of neural anoxia and spreading depression in the patient.